The BOTTOM LINE: Bispecific antibodies are new upcoming therapies for myeloma patients. There are many types of bispecific antibodies currently in clinical trials. They are expected to be approved for use in myeloma in the near future.
Please note that Ask Dr. Durie is designed to address myeloma questions of the broadest possible audience interest. If you have a question of a personal nature, please contact our InfoLine Coordinators at 800.452.2873 or [email protected] (Please do not send email attachments or lab reports.).
Dr. Brian G.M. Durie: This week's "Ask Dr. Durie" comes from a patient who has heard a lot of news about a new type of treatment called bispecific monoclonal antibodies and wants to know, what are these going to be important new therapies or what's the story about these new bispecific antibodies? Well, the answer is that these are indeed important new therapies. The bispecific antibodies, as the name suggests, bind to two types of cells.
So, in addition to binding to the myeloma, the antibody binds to immune cells, usually T cells, but can also be other cells called NK cells in the microenvironment surrounding the myeloma. These bispecific monoclonal antibodies, harness the immune cells, the T cells, for example, to jointly attack the myeloma and achieve a much better level of attack and killing of the myeloma.
And so, this is quite promising to produce better results and achieve a deeper response. The targets for these bispecifics are similar to other immune therapies and mostly to BCMA, B-cell maturation antigen, on the surface of the myeloma. But there are some other new or targeted ones. GPRC5D, for example, is another one with a specific monoclonal directed against that.
The initial results in the relapsed/refractory setting have been very promising, mostly in the 60 to 70% range. A number of these patients have received prior therapy directed against BCMA. And so, it's been encouraging to see that these patients continue to respond. It seems that this will be an important new avenue of treatment and an ongoing new modality.
These therapies are given either intravenously or by subcutaneous injection on an outpatient basis, but also an ongoing basis. And so, there's an ongoing deepening response as treatment is continued.
And so THE BOTTOM LINE, in this case, is that bispecifics are important new therapies. There are several types, and it is anticipated that in the coming months to a year or two, there will be several of these bispecific monoclonal antibodies approved by regulators, both by the FDA and in Europe, by the EMA, and available for broad use. So, very encouraging to have this new immune approach to therapy.
Professor of Medicine, Hematologist/Oncologist, and Honoree MD at the University of Brussels, Dr. Brian G.M. Durie is a co-founder of the IMF.
